Skip to main content

Advertisement

Log in

The role of targeted therapies in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

  • TOPIC REVIEW & CLINICAL GUIDELINES
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Question

What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma?

Targeted population

This recommendation applies to adult patients with progressive glioblastoma

Recommendations

Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months.

Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118(8):2163–2172

    Article  PubMed Central  PubMed  Google Scholar 

  2. Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212

    Article  PubMed  Google Scholar 

  3. Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18(3):e126–e136

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93(1):1–23

    Article  PubMed  Google Scholar 

  5. Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89(3):255–258

    Article  PubMed  Google Scholar 

  6. Institute NC (2012) Targeted Cancer Therapies Fact Sheet. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted. Accessed 1 Dec 2012

  7. Cloughesy TF, Mischel PS (2011) New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res 17(1):6–11

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410

    Article  CAS  PubMed  Google Scholar 

  9. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15(4):297–310

    Article  CAS  PubMed  Google Scholar 

  10. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18

    Article  CAS  PubMed  Google Scholar 

  11. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364

    Article  CAS  PubMed  Google Scholar 

  12. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622

    Article  CAS  PubMed  Google Scholar 

  13. Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78(3):281–293

    Article  CAS  PubMed  Google Scholar 

  14. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777):1171–1175

    Article  CAS  PubMed  Google Scholar 

  15. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049

    Article  CAS  PubMed  Google Scholar 

  16. Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15(3):339–347

    Article  CAS  PubMed  Google Scholar 

  17. Zheng PP, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM (2007) Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 62(1):40–48

    Article  CAS  PubMed  Google Scholar 

  18. Chamberlain MC, Raizer J (2009) Antiangiogenic therapy for high-grade gliomas. CNS Neurol Disord: Drug Targets 8(3):184–194

    Article  CAS  Google Scholar 

  19. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578

    CAS  PubMed  Google Scholar 

  20. Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncology 9(1):29–38

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972

    Article  PubMed  Google Scholar 

  22. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740

    Article  CAS  PubMed  Google Scholar 

  23. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96(2):259–269

    Article  CAS  PubMed  Google Scholar 

  25. Burkhardt JK, Riina H, Shin BJ et al (2012) Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 77(1):130–134

    Article  PubMed Central  PubMed  Google Scholar 

  26. Marx GM, Pavlakis N, McCowatt S et al (2001) Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54(1):31–38

    Article  CAS  PubMed  Google Scholar 

  27. Iwamoto FM, Lamborn KR, Robins HI et al (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncology 12(8):855–861

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. de Groot JF, Lamborn KR, Chang SM et al (2011) Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29(19):2689–2695

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  29. Fine HA, Wen PY, Maher EA et al (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21(12):2299–2304

    Article  CAS  PubMed  Google Scholar 

  30. Groves MD, Puduvalli VK, Chang SM et al (2007) A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3):271–277

    Article  CAS  PubMed  Google Scholar 

  31. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Reardon DA, Vredenburgh JJ, Desjardins A et al (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101(1):57–66

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncology 7(3):369

    Google Scholar 

  34. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258–1260

    Article  CAS  PubMed  Google Scholar 

  35. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259

    Article  CAS  PubMed  Google Scholar 

  36. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30(6 Suppl 19):10–14

    Article  PubMed  Google Scholar 

  37. Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181–193

    Article  PubMed  Google Scholar 

  38. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729

    Article  CAS  PubMed  Google Scholar 

  39. Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516–1525

    CAS  PubMed  Google Scholar 

  40. Cloughesy TF, Filka E, Kuhn J et al (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97(9 Suppl):2381–2386

    Article  CAS  PubMed  Google Scholar 

  41. Raymond E, Fabbro M, Boige V et al (2003) Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 14(4):603–614

    Article  CAS  PubMed  Google Scholar 

  42. Prados MD, Lamborn K, Yung WK et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncology 8(2):189–193

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27(2):149–155

    Article  CAS  PubMed  Google Scholar 

  44. Chamberlain MC, Kormanik PA (1999) Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 56(6):703–708

    Article  CAS  PubMed  Google Scholar 

  45. Reardon DA, Desjardins A, Vredenburgh JJ et al (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101(12):1986–1994

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Desjardins A, Reardon DA, Coan A et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118(5):1302–1312

    Article  CAS  PubMed  Google Scholar 

  47. Reardon DA, Desjardins A, Peters KB et al (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117(23):5351–5358

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Reardon DA, Desjardins A, Peters KB et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Chinnaiyan P, Chowdhary S, Potthast L et al (2012) Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncology 14(1):93–100

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Kang TY, Jin T, Elinzano H, Peereboom D (2008) Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 89(1):113–118

    Article  CAS  PubMed  Google Scholar 

  51. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787

    Article  CAS  PubMed  Google Scholar 

  52. Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91(3):329–336

    Article  CAS  PubMed  Google Scholar 

  53. Poulsen HS, Grunnet K, Sorensen M et al (2009) Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48(1):52–58

    Article  CAS  PubMed  Google Scholar 

  54. Zhang W, Qiu XG, Chen BS et al (2009) Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Chin Med J 122(11):1250–1254

    CAS  PubMed  Google Scholar 

  55. Quant EC, Norden AD, Drappatz J et al (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncology 11(5):550–555

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncology 12(12):1300–1310

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Lu-Emerson C, Norden AD, Drappatz J et al (2011) Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol 104(1):287–291

    Article  CAS  PubMed  Google Scholar 

  58. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131–1138

    Article  CAS  PubMed  Google Scholar 

  59. Moen MD (2010) Bevacizumab: in previously treated glioblastoma. Drugs 70(2):181–189

    Article  CAS  PubMed  Google Scholar 

  60. Chamberlain MC (2008) Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26(6):1012–1013; author reply 1013

    Google Scholar 

  61. Yung WK, Kyritsis AP, Gleason MJ, Levin VA (1996) Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2(12):1931–1935

    CAS  PubMed  Google Scholar 

  62. Kaba SE, Kyritsis AP, Conrad C et al (1997) The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol 34(2):145–151

    Article  CAS  PubMed  Google Scholar 

  63. Puduvalli VK, Yung WK, Hess KR et al (2004) Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium study. J Clin Oncol 22(21):4282–4289

    Article  CAS  PubMed  Google Scholar 

  64. See SJ, Levin VA, Yung WK, Hess KR, Groves MD (2004) 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncology 6(3):253–258

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Jaeckle KA, Hess KR, Yung WK et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21(12):2305–2311

    Article  CAS  PubMed  Google Scholar 

  66. Levin VA, Giglio P, Puduvalli VK et al (2006) Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78(1):85–90

    Article  CAS  PubMed  Google Scholar 

  67. Couldwell WT, Surnock AA, Tobia AJ et al (2011) A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 117(21):4905–4915

    Article  CAS  PubMed  Google Scholar 

  68. Couldwell WT, Hinton DR, Surnock AA et al (1996) Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2(4):619–622

    CAS  PubMed  Google Scholar 

  69. Bushunow P, Reidenberg MM, Wasenko J et al (1999) Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43(1):79–86

    Article  CAS  PubMed  Google Scholar 

  70. Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG (2000) Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol 46(3):249–259

    Article  CAS  PubMed  Google Scholar 

  71. Oudard S, Carpentier A, Banu E et al (2003) Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 63(1):81–86

    Article  PubMed  Google Scholar 

  72. Chang SM, Wen P, Cloughesy T et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23(4):357–361

    Article  CAS  PubMed  Google Scholar 

  73. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23(23):5294–5304

    Article  CAS  PubMed  Google Scholar 

  74. Grossman SA, Alavi JB, Supko JG et al (2005) Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncology 7(1):32–40

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Wen PY, Yung WK, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899–4907

    Article  CAS  PubMed  Google Scholar 

  76. Raymond E, Brandes AA, Dittrich C et al (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26(28):4659–4665

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Cloughesy TF, Wen PY, Robins HI et al (2006) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24(22):3651–3656

    Article  CAS  PubMed  Google Scholar 

  78. Rudek MA, New P, Mikkelsen T et al (2011) Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol 105(2):375–381

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  79. Wen PY, Schiff D, Cloughesy TF et al (2011) A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncology 13(4):437–446

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Bogdahn U, Hau P, Stockhammer G et al (2011) Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncology 13(1):132–142

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22(1):133–142

    Article  CAS  PubMed  Google Scholar 

  82. Franceschi E, Cavallo G, Lonardi S et al (2007) Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96(7):1047–1051

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  83. Preusser M, Gelpi E, Rottenfusser A et al (2008) Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. J Neurooncol 89(2):211–218

    Article  CAS  PubMed  Google Scholar 

  84. van den Bent MJ, Brandes AA, Rampling R et al (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27(8):1268–1274

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  85. Raizer JJ, Abrey LE, Lassman AB et al (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncology 12(1):95–103

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Raizer JJ (2005) HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74(1):77–86

    Article  CAS  PubMed  Google Scholar 

  87. da Fonseca CO, Schwartsmann G, Fischer J et al (2008) Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70(3):259–266; discussion 266–257

    Google Scholar 

  88. da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T (2011) Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137(2):287–293

    Article  PubMed  CAS  Google Scholar 

  89. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610–5617

    Article  CAS  PubMed  Google Scholar 

  90. Gilbert MR, Kuhn J, Lamborn KR et al (2012) Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106(1):147–153

    Article  CAS  PubMed  Google Scholar 

  91. Galanis E, Jaeckle KA, Maurer MJ et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27(12):2052–2058

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  92. Graff JR, McNulty AM, Hanna KR et al (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65(16):7462–7469

    Article  CAS  PubMed  Google Scholar 

  93. Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  94. Kunwar S, Chang S, Westphal M et al (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncology 12(8):871–881

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  95. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK (2006) Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5(3):239–250

    CAS  PubMed  Google Scholar 

  96. Mason WP, Belanger K, Nicholas G et al (2012) A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. J Neurooncol 107(2):343–349

    Article  CAS  PubMed  Google Scholar 

  97. Iwamoto FM, Lamborn KR, Kuhn JG et al (2011) A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncology 13(5):509–516

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  98. Friday BB, Anderson SK, Buckner J et al (2012) Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncology 14(2):215–221

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Doherty L, Gigas DC, Kesari S et al (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67(1):156–158

    Article  CAS  PubMed  Google Scholar 

  100. Reardon DA, Desjardins A, Vredenburgh JJ et al (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96(2):219–230

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  101. Hochberg F, Prados M, Russell C et al (1997) Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I–II study. J Neurooncol 32(1):45–55

    Article  CAS  PubMed  Google Scholar 

  102. Prados MD, Schold SJS, Fine HA et al (2003) A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncology 5(2):96–103

    CAS  PubMed Central  PubMed  Google Scholar 

  103. Reardon DA, Egorin MJ, Quinn JA et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23(36):9359–9368

    Article  CAS  PubMed  Google Scholar 

  104. Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97(12):6242–6244

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  105. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12(2):259–266

    Article  CAS  PubMed  Google Scholar 

  106. Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16(10):1702–1708

    Article  CAS  PubMed  Google Scholar 

  107. Brandes AA, Ermani M, Turazzi S et al (1999) Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17(2):645–650

    CAS  PubMed  Google Scholar 

  108. Rodriguez LA, Prados M, Silver P, Levin VA (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64(12):2420–2423

    Article  CAS  PubMed  Google Scholar 

  109. Vertosick FT Jr, Selker RG, Pollack IF, Arena V (1992) The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of “failed” patients. Neurosurgery 30(6):897–902; discussion 902–893

    Google Scholar 

  110. Tang P, Roldan G, Brasher PM et al (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78(3):311–316

    Article  CAS  PubMed  Google Scholar 

  111. Kesari S, Schiff D, Doherty L et al (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncology 9(3):354–363

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  112. Puduvalli VK, Giglio P, Groves MD et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncology 10(2):216–222

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  113. de Groot JF, Gilbert MR, Aldape K et al (2008) Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89–97

    Article  PubMed  CAS  Google Scholar 

  114. Hasselbalch B, Lassen U, Hansen S et al (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncology 12(5):508–516

    CAS  PubMed Central  PubMed  Google Scholar 

  115. Walbert T, Gilbert MR, Groves MD et al (2011) Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102(2):273–280

    Article  CAS  PubMed  Google Scholar 

  116. Chang SM, Barker FG 2nd, Huhn SL et al (1998) High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol 37(2):169–176

    Article  CAS  PubMed  Google Scholar 

  117. Grossman SA, Phuphanich S, Lesser G et al (2001) Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 19(13):3260–3266

    CAS  PubMed  Google Scholar 

  118. Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WK (1997) All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol 34(2):193–200

    Article  CAS  PubMed  Google Scholar 

  119. Chang SM, Kuhn JG, Robins HI et al (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17(3):984–990

    CAS  PubMed  Google Scholar 

  120. Chow KL, Gobin YP, Cloughesy T, Sayre JW, Villablanca JP, Vinuela F (2000) Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. Am J Neuroradiol 21(3):471–478

    Google Scholar 

  121. Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4):708–715

    CAS  PubMed  Google Scholar 

  122. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M (2001) Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 51(1):41–45

    Article  CAS  PubMed  Google Scholar 

  123. Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK (2002) CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest 20(7–8):948–954

    Article  CAS  PubMed  Google Scholar 

  124. Spence AM, Peterson RA, Scharnhorst JD, Silbergeld DL, Rostomily RC (2004) Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 70(1):91–95

    Article  PubMed  Google Scholar 

  125. Phuphanich S, Baker SD, Grossman SA et al (2005) Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncology 7(2):177–182

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  126. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B (2006) Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther 5(1):40–47

    Article  CAS  PubMed  Google Scholar 

  127. Hau P, Fabel K, Baumgart U et al (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100(6):1199–1207

    Article  CAS  PubMed  Google Scholar 

  128. Norden AD, Drappatz J, Muzikansky A et al (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92(2):149–155

    Article  CAS  PubMed  Google Scholar 

  129. Zustovich F, Lombardi G, Pastorelli D et al (2010) Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome. Anticancer Res 30(12):5213–5216

    CAS  PubMed  Google Scholar 

  130. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068

    Google Scholar 

  131. Brennan C, Momota H, Hambardzumyan D et al (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4(11):e7752

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  132. Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Holland EC, Michor F (2012) A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol 8(1):e1002337

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  133. Ellis LM, Hicklin DJ (2009) Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 15(24):7471–7478

    Article  CAS  PubMed  Google Scholar 

  134. Maitland ML, Hudoba C, Snider KL, Ratain MJ (2010) Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res 16(21):5296–5302

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  135. Zia MI, Siu LL, Pond GR, Chen EX (2005) Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 23(28):6982–6991

    Article  CAS  PubMed  Google Scholar 

  136. Trippa L, Lee EQ, Wen PY et al (2012) Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 30(26):3258–3263

    Article  PubMed Central  PubMed  Google Scholar 

  137. Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843–7848

    Article  CAS  PubMed  Google Scholar 

  138. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22

    Article  CAS  PubMed  Google Scholar 

  139. Oliner J, Min H, Leal J et al (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507–516

    Article  CAS  PubMed  Google Scholar 

  140. Rempel SA, Dudas S, Ge S, Gutierrez JA (2000) Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6(1):102–111

    CAS  PubMed  Google Scholar 

  141. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  142. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8(2):97–106

    Article  CAS  PubMed  Google Scholar 

  143. Hadjipanayis CG, Van Meir EG (2009) Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 15(11):519–530

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  144. Bodmer S, Strommer K, Frei K et al (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143:3222–3229

    CAS  PubMed  Google Scholar 

  145. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5(10):2963–2970

    CAS  PubMed  Google Scholar 

  146. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M (2011) Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol 2011:732413

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  147. Fecci PE, Ochiai H, Mitchell DA et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158–2167

    Article  CAS  PubMed  Google Scholar 

  148. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  149. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24(2):207–212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  150. Morgan RA, Johnson LA, Davis JL et al (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23(10):1043–1053

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  151. Ahmed N, Salsman VS, Kew Y et al (2010) HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16(2):474–485

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  152. Brown CE, Starr R, Aguilar B et al (2012) Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 18(8):2199–2209

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  153. Bullain SS, Sahin A, Szentirmai O et al (2009) Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol 94(3):373–382

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  154. Alexander BM, Mehta MP (2011) Role of isocitrate dehydrogenase in glioma. Expert Rev Neurother 11(10):1399–1409

    Article  CAS  PubMed  Google Scholar 

  155. Dang L, Jin S, Su SM (2010) IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16(9):387–397

    Article  CAS  PubMed  Google Scholar 

  156. McEllin B, Camacho CV, Mukherjee B et al (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 70(13):5457–5464

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  157. McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the AANS/CNS Joint Guidelines Committee for their review, comments and suggestions, the contributions of Laura Mitchell, CNS Guidelines Manager for organizational assistance, Maxine Brown for searching for and retrieving literature and Amy Allison for reference library consultations. We would also like to acknowledge the following individual JGC members for their contributions throughout the review process: Sepideh Amin-Hanjani, MD, FAANS, FACS, FAHA, Martina Stippler, MD, Alexander Khalessi, MD, Isabelle Germano, MD, Sean D. Christie, MD, FRCS (C), Gregory J. Zipfel, MD, Zachary Litvack, MD, MCR, Ann Marie Flannery, MD, Patricia B Raksin, MD, Joshua M. Rosenow, MD, FACS, Steven Casha, MD, PhD, Julie G. Pilitsis, MD, PhD, Gabriel Zada, MD, Adair Prall, Krystal Tomei, MD, Gregory W Hawryluk, MD.

Conflict of interest

Task Force Members report potential COIs prior to beginning work on the guideline and at the time of publication. COI disclosures are reviewed by the Task Force Chair and taken into consideration when determining writing assignments. Resolution of potential COIs included Task Force members were assigned to chapters that did not involve or in any way relate to the potential COIs disclosed.

Funding

These guidelines were funded exclusively by the CNS and Tumor Section of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons whom received no funding from outside commercial sources to support the development of this document unless otherwise stated in this section.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeffrey J. Olson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olson, J.J., Nayak, L., Ormond, D.R. et al. The role of targeted therapies in the management of progressive glioblastoma. J Neurooncol 118, 557–599 (2014). https://doi.org/10.1007/s11060-013-1339-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1339-4

Keywords

Navigation